GlassScriptPhysician profile
Lauren G Rothstein
NPI 1619395902
$5,961.47
in general payments reported to CMS, 2019-2025
30 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $512 · 2022: $1,201 · 2023: $1,539 · 2024: $1,266 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,248.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,205.65 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,013.83 | 2021-2025 | Dupixent |
| Amgen INC. | $505.02 | 2021-2025 | Tezspire, Actimmune |
| Astrazeneca Pharmaceuticals LP | $344.49 | 2021-2025 | Tezspire, Airsupra |
| Kaleo, INC. | $309.99 | 2022-2024 | Auvi-Q |
| Genzyme Corporation | $306.28 | 2022-2025 | |
| Pfizer INC. | $297.86 | 2022-2025 | |
| Incyte Corporation | $252.29 | 2021-2025 | Opzelura |
| Grifols USA, LLC | $207.26 | 2022-2025 | Xembify |
| Optinose US, INC. | $202.12 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $182.66 | 2023-2025 | |
| Abbvie INC. | $161.54 | 2022-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $153.68 | 2023-2025 | Glassia, Takhzyro, Cuvitru |
| Genentech USA, INC. | $126.44 | 2023-2025 | Xolair |
| Biocryst US Sales Co., LLC | $96.75 | 2024-2025 | Orladeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $86.25 | 2022-2024 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $69.64 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $67.84 | 2022 | |
| Bio Products Laboratory USA, INC. | $53.81 | 2022 | |
| Hikma Pharmaceuticals USA | $52.95 | 2022-2024 | Ryaltris |
| Octapharma USA, INC. | $52.81 | 2021-2023 | Cutaquig |
| Lilly USA, LLC | $41.56 | 2024-2025 | Ebglyss |
| Horizon Therapeutics Plc | $36.79 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $25.84 | 2022 | |
| Galderma Laboratories, L.P. | $23.42 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $20.30 | 2023 | |
| Leo Pharma INC. | $20.22 | 2022 | |
| Aytu Biopharma, INC. | $17.90 | 2022 | |
| Uswm, LLC | $13.52 | 2021 | |
| Alk-Abello, INC | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Rothstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.